Canine osteoarthritis management has been transformed by new biological therapies that provide effective pain relief with favorable safety profiles.
Canine osteoarthritis management has reached a transformative moment with the development and approval of anti-NGF monoclonal antibody therapy that provides effective pain relief through a mechanism distinct from NSAIDs. The monthly injection eliminates the compliance challenges of daily oral medication and removes gastrointestinal and renal side effect concerns that limit NSAID use in some dogs. For the large population of dogs with concurrent renal disease and osteoarthritis where NSAIDs are contraindicated, Librela provides an effective pain management option previously unavailable. The welfare significance is substantial since osteoarthritis affects tens of millions of dogs globally and is the most common cause of chronic pain in the canine population. The combination of anti-NGF antibody therapy with physiotherapy, hydrotherapy, weight management, and home environmental modification (ramps, orthopedic beds, non-slip flooring) produces the best welfare outcomes across all life stages of the disease.